Tapeworm drug inhibits colon cancer metastasis

June 17, 2011

A compound that for about 60 years has been used as a drug against tapeworm infection is also apparently effective against colon cancer metastasis, as studies using mice have now shown. The compound silences a gene that triggers the formation of metastases in colon cancer. Professor Ulrike Stein (Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, (MDC)) and her research group made this discovery in collaboration with Professor Robert H. Shoemaker of the National Cancer Institute (NCI) in Frederick, Maryland. Plans are already underway with Professor Peter M. Schlag (Charite Comprehensive Cancer Center) to conduct a clinical trial.

Colon cancer is one of the most common tumor diseases in Western countries. In Germany alone, there are approximated 73 000 new cases of the disease every year. Despite surgery, chemotherapy and radiation therapy, only about half of the affected patients are cured.

The reason is that around 20 percent of the patients already have at diagnosis and in about one third of the patients, metastasis occurs despite successful initial treatment. Of these patients with metastatic colon cancer, the five-year survival rate is only about 10 percent. By contrast, for nonmetastatic colon cancer patients the survival rate is 90 percent.

Scientists have known for several years that the gene S100A4/metastasin can initiate colon . Five years ago Professor Stein, working together with Professor Schlag and Professor Walter Birchmeier (MDC), showed how this gene is regulated. They found that the beta-catenin gene, when mutant, activates this S100A4/metastasin gene, thus triggering colon cancer metastasis. Beta-catenin normally regulates cellular adhesion.

The scientists looked for compounds that block the expression of the metastasin gene. They screened 1280 compounds and found what they were looking for: niclosamide, a drug until now approved for use to treat intestinal parasite infections from tapeworms.

Surprisingly, the researchers discovered that niclosamide inhibits the beta catenin-driven expression of the S100A4/metastasin gene, both in the cell culture and in mice. The animals had fewer metastases. Next, the researchers want to conduct clinical trials to find out whether the compound is also effective in patients with metastasizing colon cancer.

More information: Journal of the National Cancer Institute, Vol. 103, No. 12, June 17, 2011.

Related Stories

Recommended for you

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Metabolism can be used to subtype hepatoblastoma tumors

September 18, 2017
Looking at cell metabolism instead of histology, EPFL scientists have identified new biomarkers that could help more accurately classify the two main subtypes of hepatoblastoma, a children liver cancer.

Scientists find bacteria in pancreatic tumors that metabolize a common drug

September 15, 2017
To the reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study published today in Science, researchers describe findings that certain bacteria can be found inside human pancreatic ...

New technologies combined to identify specific DNA defect underlying a type of cancer

September 15, 2017
(Medical Xpress)—A team of researchers from the Netherlands and the U.K. has developed a technique for studying inherited types of cancers using two relatively new technologies—organoid development and CRISPR/Cas9. In ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.